Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

A Million Conversations is Sanofi’s global initiative to rebuild trust in healthcare with the underrepresented. Specifically with Black and ethnic minority groups, women, people with disabilities, and ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...

The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.

We are dedicated to supporting the autoimmune type 1 diabetes community by exploring innovative therapies that have the potential to improve outcomes for millions of people living with the condition.